I-CHUN CHENHu, Fu-ChangFu-ChangHuCHING-HUNG LINHuang, Shu-MinShu-MinHuangDWANG-YING CHANGANN-LII CHENGYEN-SHEN LU2022-11-072022-11-072021-100960-9776https://scholars.lib.ntu.edu.tw/handle/123456789/624457This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of progression-free survival (PFS) and this extra-prolongation of median survival time in OS relates specifically to the anti-HER2 antibody.enHER2; Metastatic breast cancer; Overall survival; Progression-free survival[SDGs]SDG3journal article10.1016/j.breast.2021.07.006342983002-s2.0-85110535616WOS:000696705600026https://scholars.lib.ntu.edu.tw/handle/123456789/597066